TABLE 1.

Impact of BMD assay modifications and supplements on exebacase MICs against 25 S. aureus isolates^a

Supplementation/modification	MIC (μg/ml)			Trailing effect
	50%	90%	Range
None	32	64	2–128	Yes
0.002% polysorbate 80	64	64	8–64	Yes
50 μg/ml Ca2+	32	64	1–128	Yes
2% NaCl	128	128	32–128	Yes
2.5% laked horse blood	32	64	4–256	Yes
5% laked horse blood	32	64	4–256	Yes
10% laked horse blood	16	32	2–128	Yes
25% laked horse blood	8	16	2–128	Yes
Polypropylene plates	16	128	4–128	Yes
0.1% BSA (polypropylene plates)	8	32	1–32	Yes
0.1% BSA	8	32	4–32	Yes
0.1% BSA, 2% NaCl, 200 rpm	32	128	8–>256	Yes
0.1% BSA, 2% NaCl	32	64	16–128	Yes
CO2 atmosphere	32	64	32–128	Yes
0.5 mM DTT	128	128	8–256	Yes
50% horse serum	0.5	2	0.125–2	No
25% horse serum	0.5	2	0.125–2	No
12.5% horse serum	1	4	0.125–4	No
6.25% horse serum	4	8	1–8	No

^aMICs were determined by broth microdilution in 96-well, round-bottom, polystyrene microtitration plates (unless otherwise indicated) according to the method described in CLSI document M07-A11 (9), with the indicated supplements and modifications.